JP2021534217A5 - - Google Patents

Info

Publication number
JP2021534217A5
JP2021534217A5 JP2021510070A JP2021510070A JP2021534217A5 JP 2021534217 A5 JP2021534217 A5 JP 2021534217A5 JP 2021510070 A JP2021510070 A JP 2021510070A JP 2021510070 A JP2021510070 A JP 2021510070A JP 2021534217 A5 JP2021534217 A5 JP 2021534217A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
improvement
reduction
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021510070A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534217A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/047305 external-priority patent/WO2020041340A1/en
Publication of JP2021534217A publication Critical patent/JP2021534217A/ja
Publication of JP2021534217A5 publication Critical patent/JP2021534217A5/ja
Pending legal-status Critical Current

Links

JP2021510070A 2018-08-21 2019-08-20 視力を改善するためのａ−２−アドレナリン受容体アゴニストの使用 Pending JP2021534217A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862720671P 2018-08-21 2018-08-21
US62/720,671 2018-08-21
PCT/US2019/047305 WO2020041340A1 (en) 2018-08-21 2019-08-20 The use of alpha-2-adrenergic receptor agonists for improving vision

Publications (2)

Publication Number Publication Date
JP2021534217A JP2021534217A (ja) 2021-12-09
JP2021534217A5 true JP2021534217A5 (https=) 2022-08-26

Family

ID=67841225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021510070A Pending JP2021534217A (ja) 2018-08-21 2019-08-20 視力を改善するためのａ−２−アドレナリン受容体アゴニストの使用

Country Status (17)

Country Link
US (4) US20210205273A1 (https=)
EP (1) EP3840750A1 (https=)
JP (1) JP2021534217A (https=)
KR (1) KR20210047323A (https=)
CN (1) CN112823003A (https=)
AR (1) AR115991A1 (https=)
AU (1) AU2019325486A1 (https=)
BR (1) BR112021003295A2 (https=)
CA (1) CA3110318A1 (https=)
CL (1) CL2021000440A1 (https=)
CO (1) CO2021003460A2 (https=)
IL (1) IL280990A (https=)
MX (1) MX2021002112A (https=)
PH (1) PH12021550372A1 (https=)
SG (1) SG11202101730SA (https=)
TW (1) TW202021584A (https=)
WO (1) WO2020041340A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115443125A (zh) * 2020-02-20 2022-12-06 阿勒根公司 α-2-肾上腺素能受体激动剂的药物组合物和其用于改善视力的用途
CA3209420A1 (en) 2021-02-24 2022-09-01 Peter Jarrett Intracanalicular depot inserter device
AU2024217271A1 (en) * 2023-02-08 2025-09-18 Bausch + Lomb Ireland Limited Alpha-2-adrenergic agonists for improving vision

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US7931909B2 (en) * 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
CN102821753A (zh) 2010-01-22 2012-12-12 阿勒根公司 前房内持续释放治疗药植入物
US20120277239A1 (en) * 2011-04-28 2012-11-01 Alpha Synergy Development Inc. Compositions and Methods for Improving Night Vision
US10507245B2 (en) * 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
WO2014143754A2 (en) 2013-03-15 2014-09-18 Allergan, Inc. Prostamide-containing intraocular implant
EP2978406A1 (en) 2013-03-27 2016-02-03 Forsight Vision5, Inc. Bimatoprost ocular silicone inserts and methods of use thereof
AU2014248460B2 (en) 2013-04-01 2019-04-11 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
CN103338483B (zh) * 2013-07-24 2016-08-10 成都西加云杉科技有限公司 数据分流方法、数据分流设备及异构网络
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US11077053B2 (en) * 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia

Similar Documents

Publication Publication Date Title
TWI361701B (en) Ophthalmic formulation for the prevention and treatment of adverse ocular conditions, particularly those associated with the aging eye
JP2023105147A5 (https=)
JP2019524826A5 (https=)
JP2017061467A5 (https=)
EP1328186A1 (en) Methods for treating various eye disorders
JP2021534217A5 (https=)
CN114585365A (zh) 在假晶状体患者中使用拟副交感神经药物单独或与一种或多种α激动剂组合以产生多焦点
EP3463349A1 (en) Use of sirolimus to treat exudative age-related macular degeneration with persistent edema
WO2019191525A1 (en) Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders
US6730691B1 (en) Uses of alpha adrenergic blocking agents
Nagpal et al. Spontaneous regression (autoinfarction) of proliferative sickle retinopathy
Choi et al. Goniotomy for steroid-induced glaucoma: clinical and tonographic evidence to support therapeutic goniotomy
JP6267003B2 (ja) ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
CN110114066A (zh) 含沙丁胺醇的眼科药物
Ruparelia et al. Multiple XEN gel stents for refractory pediatric glaucoma
US20130317058A1 (en) Ophthalmic composition for enabling dilation of pupils
JP2023514732A5 (https=)
Kang et al. Phacoemulsification and posterior chamber intraocular lens implantation in uveitis.
Pérez-Sarriegui et al. Phaco-non-penetrating deep sclerectomy in ocular hypertension secondary to dexamethasone intravitreal implant
de Klerk et al. I-Stent for treatment of angle recession with raised intraocular pressure.
Connor Jr et al. Management of aphakic and pseudophakic cystoid macular edema
US20260083730A1 (en) Methods of treating eye disorders
RU2021106014A (ru) Применение агонистов альфа-2-адренергических рецепторов для улучшения зрения
Hill et al. Year in review of optometric advancements
WO2025005896A1 (en) Ophthalmic viscoelastic formulations suitable for use in cataract surgery